Skip to main navigation menu Skip to main content Skip to site footer

TIZIMLI QIZIL YUGURIKDA INTERFERON-STIMULLANGAN GENLAR MUTATSIYASI HAMDA ULARNING KLINIK-MOLEKULYAR GENETIK ASOSLARI.

Abstract

So‘nggi yillarda tug‘ma va orttirilgan immunitetning molekulyar asoslarini chuqurroq o‘rganish natijasida ushbu interferonlarning autoimmun kasalliklardagi roli qayta ko‘rib chiqildi. Bugungi kunga kelib, interferon tomonidan tartibga solinadigan ko‘plab genlar — “interferon imzosi genlari” (IFN signature genes) aniqlangan. Ushbu genlarning ekspressiyasi tizimli qizil yugurik (TQY) bilan kasallangan bemorlarda sezilarli darajada ortgani aniqlangan, bu esa I tip va III tip interferonlarning TQY patogenezidagi muhim rolini ko‘rsatadi.

Keywords

Tizimli qizil yugurik, interferon, T-limfotsit yoki T-hujayra, avtoimmunitet, sitokinlar, anifrolumab, sifalimumab, rontalizumab.

PDF

References

  1. Crow MK. Type I interferon in the pathogenesis of lupus. J Immunol. 2014;192(12):5459–5468. doi:10.4049/jimmunol.1002795
  2. Khamashta M, et al. Anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382(3):211–221. doi:10.1056/NEJMoa1912196
  3. Niewold TB. Interferon alpha as a primary pathogenic factor in human lupus. J Interferon Cytokine Res. 2011;31(12):887–892.
  4. Dörner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet. 2019;393(10188):2344–2358. doi:10.1016/S0140-6736(19)30546-X.
  5. Morand EF, et al. Trial of Anifrolumab in Active Systemic Lupus Erythematosus. N Engl J Med. 2020;382(3):211–221. [DOI:10.1056/NEJMoa1912196]
  6. Figueiredo-Braga M, et al. IL-17 and IFN pathways in systemic lupus erythematosus: convergence and therapeutic implications. Autoimmun Rev. 2022;21(9):103154. [DOI:10.1016/j.autrev.2022.103154]
  7. Rodríguez-Carrio J et al. Th17 responses and IL-23/IL-17 axis in lupus nephritis. Rheumatology. 2020;59(9):2461-2470. doi:10.1093/rheumatology/keaa078